Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 2/20 | 0.60 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.60 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.60 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14356547 | 0.77 | PI4KA (0.66) | PI4KAPI4K2BPI4K2API4KBCYP1A2 | |
| SCHEMBL9604572 | 0.77 | CYP1A2 (0.69) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL9705702 | 0.75 | CYP1A2 (0.62) | CYP1A2CYP2D6MAPK1 | |
| SCHEMBL10248598 | 0.75 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBCYP1A2 | |
| SCHEMBL21126195 | 0.75 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4569753 | 0.75 | PI4KA (0.64) | PI4KAPI4K2BPI4K2API4KBCYP1A2 | |
| SCHEMBL5021593 | 0.75 | PI4KA (1.00) | PI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL8466944 | 0.74 | CYP1A2 (0.49) | PI4KAPI4K2BPI4K2API4KBCYP1A2 | |
| SCHEMBL12194505 | 0.72 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KBCYP1A2 | |
| SCHEMBL10149296 | 0.72 | PI4KA (0.60) | PI4KAPI4K2BPI4K2API4KB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | BEIJING XUANYI PHARMASCIENCES CO., LTD. (CN) | 2023-10-03 | — | — | US | disclosed |
| US-20230257413-A1 | ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | RIKEN GENESIS CO., LTD. (JP) | 2023-08-17 | — | — | US | disclosed |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | AJ SCIENCES (YIXING) CO., LTD (CN) | 2020-10-22 | — | — | US | disclosed |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. | 2013-10-31 | — | — | US | disclosed |
| US-8497278-B2 | Imidazo[1,2-a]pyridine compounds | SUNOVION PHARMACEUTICALS INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | SUNOVION PHARMACEUTICALS INC. (US) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166146-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PI4KA 924/4885PI4K2B 1442/4885PI4K2A 854/4885 |
| US-20230257413-A1 | ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF | NSUN2, NSUN3, POLRMT | PI4KA 3910/4885PI4K2B 4406/4885PI4K2A 4334/4885 |
| US-20130289013-A1 | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS | PAICS, ITPA, DPYD | PI4KA 924/4885PI4K2B 1442/4885PI4K2A 854/4885 |
| US-20200331957-A1 | CYCLIC DI-NUCLEOTIDES AS STIMULATOR OF INTERFERON GENES MODULATORS | STING1, IRF3, CGAS | PI4KA 2615/4885PI4K2B 2369/4885PI4K2A 2302/4885 |
| US-11773132-B2 | Cyclic di-nucleotides as stimulator of interferon genes modulators | STING1, IRF3, CGAS | PI4KA 2615/4885PI4K2B 2369/4885PI4K2A 2302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.